Geron Corporation (GERN) Stock Score, Valuation & Financial Research
Geron Corporation is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 20/100.
Quick answer for GERN
Geron Corporation currently has a Wall Street Score of 20/100. The stored market price is $1.35. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is +0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Geron Corporation does
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
GERN financial snapshot
- Wall Street Score:
- 20/100
- Current price:
- $1.35
- Market capitalization:
- $866.1M
- Revenue:
- $204.6M
- Net income:
- $-69.9M
- Free cash flow:
- $-111.1M
- Cash:
- $62.6M
- Total debt:
- $122.1M
- EPS:
- -0.10
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 33/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-111.1M, showing cash burn in the current stored period.
- The balance sheet shows $62.6M of cash versus $122.1M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.1 points: GERN increased 0.1 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-04.
How to research GERN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.